Investigate the Effect on the QT/QTc interval of Repeated and Escalating Doses of AZD3480 during 6 Days - TQT

Study identifier:D3690C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double-blind, Randomised, Multicentre, Placebo-controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc interval of Repeated and Escalating Doses of AZD3480 during 6 Days, using Moxifloxacin as a Positive Control, in Healthy Male Volunteers, CYP2D6 Extensive and Poor Metabolisers.

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3480, Moxifloxacin, PLACEBO

Sex

Male

Actual Enrollment

Study type

Interventional

Age

20 Years - 60 Years

Date

Study Start Date: 01 Jan 2008

Primary Completion Date: 01 Aug 2008

Study Completion Date: 01 Aug 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Escalating doses of AZD3480 during 6 days	Drug: AZD3480 Capsule, oral, single dose, 6 days Other Name: TC-1734-226
Experimental: 2 Repeated doses of AZD3480 during 6 days	Drug: AZD3480 Capsule, oral, single dose, 6 days Other Name: TC-1734-226
Placebo Comparator: 3 Placebo during 6 days	Drug: PLACEBO Capsule, oral, single dose
Active Comparator: 4 Placebo during 5 days, active day 6	Drug: Moxifloxacin Capsule(encapsulated), oral, single dose Other Name: Moxifloxacin

"There is no result for the study"

Documents available

D3690C00004 Clinical Study Report Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

Anneli Thuresson

+46 31 776 1381

Investigators

Principal Investigator

Hans-Göran Hårdemark

Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden